Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.

Stühmer, Thorsten; Arts, Janine; Chatterjee, Manik; Borawski, Johanna; Wolff, André; King, Peter; Einsele, Hermann; Leo, Eugen; Bargou, Ralf C

Stühmer, Thorsten; Arts, Janine; Chatterjee, Manik; Borawski, Johanna; Wolff, André; King, Peter; Einsele, Hermann; Leo, Eugen; Bargou, Ralf C.

Affiliation

Stühmer T; Department of Internal Medicine II, Division of Haematology, University Hospital of Würzburg, Würzburg, Germany. stuehmer_t@medizin.uni-wuerzburg.de

Br J Haematol ; 149(4): 529-36, 2010 May.

Article in En | MEDLINE | ID: mdl-20331455

Subject(s)

Antineoplastic Agents/pharmacology; Histone Deacetylase Inhibitors/pharmacology; Hydroxamic Acids/pharmacology; Multiple Myeloma/pathology; Acetylation/drug effects; Antineoplastic Combined Chemotherapy Protocols/pharmacology; Apoptosis/drug effects; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical/methods; Histones/metabolism; Humans; Multiple Myeloma/metabolism; Tumor Cells, Cultured

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Histone Deacetylase Inhibitors / Hydroxamic Acids / Multiple Myeloma / Antineoplastic Agents Limits: Humans Language: En Journal: Br J Haematol Year: 2010 Document type: Article Affiliation country: Germany Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google